Palmar plantar erythrodysesthesia primary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
* Application of ointment containing antioxidants with high radical protection factors can effectively prevent the development of PPE.<ref name="pmid23969763">{{cite journal| author=Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A et al.| title=Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. | journal=Skin Pharmacol Physiol | year= 2014 | volume= 27 | issue= 2 | pages= 66-70 | pmid=23969763 | doi=10.1159/000351801 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23969763 }}</ref> | * Application of ointment containing antioxidants with high radical protection factors can effectively prevent the development of PPE.<ref name="pmid23969763">{{cite journal| author=Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A et al.| title=Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. | journal=Skin Pharmacol Physiol | year= 2014 | volume= 27 | issue= 2 | pages= 66-70 | pmid=23969763 | doi=10.1159/000351801 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23969763 }}</ref> | ||
* In a randomized control trial in patients that were using pegylated liposomal doxorubicin, it was proven that reduction of dose intensity can effectively prevent PPE. When the dose of PLD is not in excess of 10mg/m(2) weekly, PPE can be easily managed. As the literature support is limited, panel of experts advise patient education and supportive measures for prevention and treatment of PPE.<ref name="pmid18331788">{{cite journal| author=von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J et al.| title=Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. | journal=Eur J Cancer | year= 2008 | volume= 44 | issue= 6 | pages= 781-90 | pmid=18331788 | doi=10.1016/j.ejca.2008.01.028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18331788 }}</ref> | * In a randomized control trial in patients that were using pegylated liposomal doxorubicin, it was proven that reduction of dose intensity can effectively prevent PPE. When the dose of PLD is not in excess of 10mg/m(2) weekly, PPE can be easily managed. As the literature support is limited, panel of experts advise patient education and supportive measures for prevention and treatment of PPE.<ref name="pmid18331788">{{cite journal| author=von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J et al.| title=Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. | journal=Eur J Cancer | year= 2008 | volume= 44 | issue= 6 | pages= 781-90 | pmid=18331788 | doi=10.1016/j.ejca.2008.01.028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18331788 }}</ref> | ||
* In another study, a group of patients were given topical ointment with PLD and observed for the development of PPE. Among the patients, 60% regularly applied cream and effectively did not develop PPE. The rest of the 40% of patients interrupted their application of ointment, from which, six developed PPE and thereafter resumed the application of ointment. As a result of restarting application, palmar plantar erythrodysesthesia completely disappeared or was strongly reduced. | * In another study, a group of patients were given topical ointment with PLD and observed for the development of PPE. Among the patients, 60% regularly applied cream and effectively did not develop PPE. The rest of the 40% of patients interrupted their application of ointment, from which, six developed PPE and thereafter resumed the application of ointment. As a result of restarting application, palmar plantar erythrodysesthesia completely disappeared or was strongly reduced.<ref name="pmid239697632">{{cite journal| author=Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A et al.| title=Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. | journal=Skin Pharmacol Physiol | year= 2014 | volume= 27 | issue= 2 | pages= 66-70 | pmid=23969763 | doi=10.1159/000351801 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23969763 }}</ref> | ||
==References== | ==References== | ||
Revision as of 22:22, 6 October 2018
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia primary prevention On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia primary prevention |
|
Palmar plantar erythrodysesthesia primary prevention in the news |
|
Blogs on Palmar plantar erythrodysesthesia primary prevention |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
|
Risk calculators and risk factors for Palmar plantar erythrodysesthesia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Primary prevention
The cooling of hands and feet may help prevent PPE (Baack and Burgdorf, 1991; Zimmerman et al, 1995).
- Dr Kuznecovs with his colleagues came to the conclusion that atorvastatin and polyprenol combination can prevent PPE due to capecitabine. https://www.medscape.com/viewarticle/848530
- Application of ointment containing antioxidants with high radical protection factors can effectively prevent the development of PPE.[1]
- In a randomized control trial in patients that were using pegylated liposomal doxorubicin, it was proven that reduction of dose intensity can effectively prevent PPE. When the dose of PLD is not in excess of 10mg/m(2) weekly, PPE can be easily managed. As the literature support is limited, panel of experts advise patient education and supportive measures for prevention and treatment of PPE.[2]
- In another study, a group of patients were given topical ointment with PLD and observed for the development of PPE. Among the patients, 60% regularly applied cream and effectively did not develop PPE. The rest of the 40% of patients interrupted their application of ointment, from which, six developed PPE and thereafter resumed the application of ointment. As a result of restarting application, palmar plantar erythrodysesthesia completely disappeared or was strongly reduced.[3]
References
- ↑ Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A; et al. (2014). "Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy". Skin Pharmacol Physiol. 27 (2): 66–70. doi:10.1159/000351801. PMID 23969763.
- ↑ von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J; et al. (2008). "Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts". Eur J Cancer. 44 (6): 781–90. doi:10.1016/j.ejca.2008.01.028. PMID 18331788.
- ↑ Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A; et al. (2014). "Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy". Skin Pharmacol Physiol. 27 (2): 66–70. doi:10.1159/000351801. PMID 23969763.